ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IPSC Century Therapeutics Inc

3.55
-0.12 (-3.27%)
Last Updated: 10:47:13
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,040
Bid Price 3.51
Ask Price 3.63
News -
Day High 3.63

Low
1.28

52 Week Range

High
5.51

Day Low 3.51
Company Name Stock Ticker Symbol Market Type
Century Therapeutics Inc IPSC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -3.27% 3.55 10:47:13
Open Price Low Price High Price Close Price Prev Close
3.53 3.51 3.63 3.67
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
67 4,040 $ 3.56 $ 14,378 - 1.28 - 5.51
Last Trade Time Type Quantity Stock Price Currency
10:53:11 25 $ 3.55 USD

Century Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
230.1M 64.82M - 2.24M -136.67M -2.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Century Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IPSC Message Board. Create One! See More Posts on IPSC Message Board See More Message Board Posts

Historical IPSC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.724.42783.253.95115,030-0.17-4.57%
1 Month4.815.2393.254.10120,362-1.26-26.20%
3 Months4.135.513.254.28219,533-0.58-14.04%
6 Months1.665.511.283.28197,8591.89113.86%
1 Year3.205.511.283.14144,6450.3510.94%
3 Years19.5032.8991.2810.46145,812-15.95-81.79%
5 Years19.5032.8991.2810.46145,812-15.95-81.79%

Century Therapeutics Description

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.

Your Recent History

Delayed Upgrade Clock